5 Dosing Strengths to Help Patients
Get Back to Feeling
ADTHYZA® has multiple doses to meet patient needs1
ADTHYZA, a natural thyroid extract (NTE), is taken orally.1
The dosage of thyroid hormones is determined by the indication and must in every case be individualized according to patient response and laboratory findings.1
USUAL STARTING DOSE
Typical starting dose is 32.5 mg with increments of 16.25 mg every 2 to 3 weeks to find the most effective dose. A lower starting dosage, 16.25 mg once a day, is recommended in patients with long-standing myxedema, particularly if cardiovascular impairment is suspected, in which case extreme caution is recommended. Reduce dosage if angina appears.1
Maintenance doses of 65 mg/d to 130 mg/d usually result in normal serum T4 and T3 levels. Adequate therapy usually results in normal thyroid-stimulating hormone (TSH) and T4 levels after 2 to 3 weeks of therapy.1
Readjust thyroid hormone dosage within the first 4 weeks of therapy after proper clinical and laboratory evaluations, including serum levels of T4, bound and free, and TSH.1
Enroll in this free premium prescription home delivery service, today!
ADTHYZA is also available through most retail pharmacies. If a pharmacy doesn’t have ADTHYZA in stock, tell your patients they should ask for it to be ordered. Most pharmacy orders are delivered in a few days—and often overnight.
Make Sure Patients Get Exactly What You Prescribe
If you and your patient decide to treat with ADTHYZA, be sure to write “Dispense as Written,” “DAW,” or “Brand Medically Necessary” on the prescription to avoid substitutions at the pharmacy. Patients who enroll in the ADTHYZA Cares program will automatically receive ADTHYZA each time.
Please note that Adthyza® has not been reviewed by the FDA for safety or efficacy.
IMPORTANT SAFETY INFORMATION
DRUGS WITH THYROID HORMONE ACTIVITY, ALONE OR TOGETHER WITH OTHER THERAPEUTIC AGENTS, HAVE BEEN USED FOR THE TREATMENT OF OBESITY. IN EUTHYROID PATIENTS, DOSES WITHIN THE RANGE OF DAILY HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION. LARGER DOSES MAY PRODUCE SERIOUS OR EVEN LIFE-THREATENING MANIFESTATIONS OF TOXICITY, PARTICULARLY WHEN GIVEN IN ASSOCIATION WITH SYMPATHOMIMETIC AMINES SUCH AS THOSE USED FOR THEIR ANORECTIC EFFECTS.
ADTHYZA® (thyroid tablets, USP) is a prescription medicine indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.
ADTHYZA® is also indicated as a pituitary TSH suppressant in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer.
ADTHYZA® is contraindicated in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any component of the product.
The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.
WARNINGS AND PRECAUTIONS:
Thyroid hormones should be used with great caution in circumstances where the integrity of the cardiovascular system is suspected. In the elderly and in patients with cardiovascular disease, ADTHYZA should be used with greater caution. In these patients, therapy should be initiated with low doses of ADTHYZA. When, in such patients, a euthyroid state can only be reached at the expense of an aggravation of the cardiovascular disease, thyroid hormone dosage should be reduced.
Thyroid hormone therapy in patients with concomitant diabetes mellitus or diabetes insipidus, or adrenal cortical insufficiency aggravates the intensity of their symptoms, and appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
Hypothyroidism decreases, and hyperthyroidism increases the sensitivity to oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants, and the dosage of the latter agents should be adjusted on the basis of frequent prothrombin time determinations. In infants, excessive doses of thyroid hormone preparations may produce craniosynostosis.
Carcinogenesis/Mutagenesis: A reportedly apparent association between prolonged thyroid therapy and breast cancer has not been confirmed, and patients on thyroid for established indications should not discontinue therapy. No confirmatory long-term studies in animals have been performed to evaluate carcinogenic potential, mutagenicity, or impairment of fertility in either males or females.
Pregnancy and Lactation: Thyroid replacement therapy for hypothyroid women should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated. Minimal amounts of thyroid hormones are excreted in human milk. However, caution should be exercised when the thyroid is administered to a nursing woman. Routine determinations of serum T4 and/or TSH are strongly advised in neonates in view of the deleterious effects of thyroid deficiency on growth and development.
Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare.
Many drugs and some laboratory tests may alter the therapeutic response to ADTHYZA®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Patients on oral anticoagulants, insulin, and oral hypoglycemics should be monitored closely during the initiation of thyroid replacement therapy.
- Oral Anticoagulants: Concomitant use of thyroid hormones with oral anticoagulants alters the sensitivity of oral anticoagulants.
- Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
- Cholestyramine or Colestipol—Cholestyramine or colestipol binds both levothyroxine (T4) and liothyronine (T3) in the intestine, thus impairing the absorption of these thyroid hormones. Four to five hours should elapse between the administration of cholestyramine or colestipol and thyroid hormones.
- Estrogen, Oral Contraceptives—Estrogens tend to increase serum thyroxine-binding globulin (TBg). In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine (T4) may be decreased when estrogens are started, thus increasing thyroid requirements. Patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogen or estrogen-containing oral contraceptives are given.
For further information, please see the accompanying complete Prescribing Information for ADTHYZA.
T4, levothyroxine; T3, liothyronine.
- 1. Adthyza [prescribing information] Woburn, MA, Azurity Pharmaceuticals, Inc. 2023 https://www.adthyza.com/hcp/assets/pdf/Adthyza-PI-Promo-June2023-R01.pdf Prescribing information